Regional citrate anticoagulation in continuous venovenous haemodiafiltration using commercial solutions
Open Access
- 1 January 2004
- journal article
- research article
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 19 (1), 171-178
- https://doi.org/10.1093/ndt/gfg488
Abstract
Background. Treatment with trisodium citrate provides an effective means of regional anticoagulation during continuous renal replacement therapy (CRRT). We evaluated the efficacy, safety and cost of a regional citrate anticoagulation protocol using commercial solutions in 17 critically ill patients treated with continuous venovenous haemodiafiltration (CVVHDF). We performed a total of 22 sessions. Methods. We delivered an A.C.D-A541® solution containing 112.9 mmol/l disodium citrate (3.22%) at a median rate of 260 (190–280) ml/h via the pre-filter port of a COBE PRISMA with an AN-69 dialyser, while adjusting the rate to maintain post-filtered ionized calcium (iCa2+) between 0.25 and 0.4 mmol/l. Plasma iCa2+ was maintained at >1.1 mmol/l by infusion of calcium chloride at a median rate of 1.70 (1.36–2.27) mmol/h. The dialysate was easily modified according to the acid–base status of each patient. Both replacement and dialysate solutions were delivered at 1200 ml/h. Each session was scheduled for 48 h and biological parameters were assessed every 6 h. Results. The mean dialyser survival was 39 ± 11 h (median 41.5 h; range 13–48 h). We observed dialyser clotting in four cases (18%). There were no bleeding events or modifications of coagulation parameters. The citrate solution, replacement solution and dialysate were obtained as commercial products. Both the replacement and dialysate solutions contained calcium. The extra cost of this technique was 25 €/day as compared to anticoagulation with heparin. Conclusions. We designed an efficient method of regional citrate anticoagulation for CVVHDF by using commercial solutions. The monitoring of patients was as intensive as during heparin anticoagulation for CRRT. Because of the higher cost of this method, it should be proposed only for patients with high bleeding risk.Keywords
This publication has 26 references indexed in Scilit:
- Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trialThe Lancet, 2000
- A controlled trial of low-molecular-weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtrationCritical Care Medicine, 1999
- Anticoagulant-induced thrombosis.JAMA, 1999
- Anticoagulation with prostaglandin E1 and unfractionated heparin during continuous venovenous hemofiltrationCritical Care Medicine, 1998
- The coagulation system in the critically ill patient with acute renal failure and the effect of an extracorporeal circuitAmerican Journal of Kidney Diseases, 1997
- Heparin use in continuous renal replacement proceduresJournal of the American Society of Nephrology, 1996
- Heparin-Induced Thrombocytopenia in Patients Treated with Low-Molecular-Weight Heparin or Unfractionated HeparinNew England Journal of Medicine, 1995
- Anticoagulation with Low Molecular Weight Heparin (Fragmin) during Continuous Hemodialysis in the Intensive Care UnitArtificial Organs, 1993
- Use of Prostacyclin as the Only Anticoagulant during Continuous Venovenous HemofiltrationPublished by S. Karger AG ,1990
- Nafamostat Mesylate as Anticoagulant in Continuous Hemofiltration and Continuous HemodiafiltrationPublished by S. Karger AG ,1990